On this basis, this review addresses the current data regarding the roles of IL-17 signaling in the pathogenesis of AILD and provides new insight into therapeutic potential of targeting IL-17-mediated responses. The gene discussed is IL17A; the disease is angioimmunoblastic T-cell lymphoma.